ReviewInternational journal of endocrinology2018
MicroRNA and Microvascular Complications of Diabetes.
Review in International journal of endocrinology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 80 citations in OpenAlex.
- A Pilot Study of Circulating microRNA Expression in Newly Diagnosed Type 2 Diabetes Using a Pooled Sample Approach.Clinics and practice · 2026Article
- Trends and Research Hotspots in Biomarkers of Sjögren's Syndrome Over the Past Two Decades: A Data-Driven Atlas Analysis.Immunity, inflammation and disease · 2026Review
- Clinical Importance of miRNA in Diabetic Neuropathy: Pathophysiology, Diagnosis, and Therapeutic Potential.Current diabetes reviews · 2026Review
- Review
- Integrating Renal and Metabolic Parameters into a Derived Risk Score for Hyperuricemia in Uncontrolled Type 2 Diabetes: A Retrospective Cross-Sectional Study in Northwest Romania.Medicina (Kaunas, Lithuania) · 2025Article
- Molecular and Pathophysiological Mechanisms Leading to Ischemic Heart Disease in Patients with Diabetes Mellitus.International journal of molecular sciences · 2025Review
- The interplay between diabetes and atherosclerosis: A review of pathophysiological mechanisms.ARYA atherosclerosis · 2025Review
- Comparative effects of metformin and varying intensities of exercise on miR-133a expression in diabetic rats: Insights from machine learning analysis.Biochemistry and biophysics reports · 2024Article
- Dysfunction of PTEN-Associated MicroRNA Regulation: Exploring Potential Pathological Links in Type 1 Diabetes Mellitus.Medicina (Kaunas, Lithuania) · 2024Article
- Circulating miRNAs associate with historical childhood asthma hospitalization in different serum vitamin D groups.Respiratory research · 2024Article
- Cordyceps cicadae polysaccharides attenuate diabetic nephropathy via the miR-30a-3p/TRIM16 axis.Journal of diabetes investigation · 2024Article
- Macrophage Activation Syndrome in Coinciding Pandemics of Obesity and COVID-19: Worse than Bad.Advances in experimental medicine and biology · 2024Review
- Serum MicroRNA-191-5p Levels in Vascular Complications of Type 1 Diabetes: The EURODIAB Prospective Complications Study.The Journal of clinical endocrinology and metabolism · 2023Article
- A mutual regulatory loop between miR-155 and SOCS1 influences renal inflammation and diabetic kidney disease.Molecular therapy. Nucleic acids · 2023Article
- The link between glycemic control measures and eye microvascular complications in a clinical cohort of type 2 diabetes with microRNA-223-3p signature.Journal of translational medicine · 2023Article
- Peripheral Neuropathy in Diabetes Mellitus: Pathogenetic Mechanisms and Diagnostic Options.International journal of molecular sciences · 2023Review
- Text mining-based identification of promising miRNA biomarkers for diabetes mellitus.Frontiers in endocrinology · 2023Article
- MicroRNA-150 (miR-150) and Diabetic Retinopathy: Is miR-150 Only a Biomarker or Does It Contribute to Disease Progression?International journal of molecular sciences · 2022Review
- Circular RNAs in Diabetic Nephropathy: Updates and Perspectives.Aging and disease · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the last decade, miRNAs have received substantial attention as potential players of diabetes microvascular complications, affecting the kidney, the retina, and the peripheral neurons. Compelling evidence indicates that abnormally expressed miRNAs have pivotal roles in key pathogenic processes of microvascular complications, such as fibrosis, apoptosis, inflammation, and angiogenesis. Moreover, clinical research into innovative both diagnostic and prognostic tools suggests circulating miRNAs as possible novel noninvasive markers of diabetes microvascular complications. In this review, we summarize current knowledge and understanding of the role of miRNAs in the injury to the microvascular bed in diabetes and discuss the potential of miRNAs as clinical biomarkers of diabetes microvascular complications.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.